Teva and Active Biotech Remain Committed to the Development of NERVENTRAA for Multiple Sclerosis Following the Negative Opinion from the EMA's CHMP JERUSALEM & LUND, Sweden-- --Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that both companies remain committed to the NERVENTRAA clinical development program for multiple ... (more)
More...
More...